Journal Article


A Kelly
S Mansoor
M Grennell
T N Walsh


Medicine & Nursing

radiotherapy adjuvant randomized controlled trials as topic mortality humans treatment outcome stomach neoplasms surgery adenocarcinoma esophageal neoplasms cardia follow up studies chemotherapy adjuvant

Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. (2002)

Abstract Sophisticated surgical approaches have a definite but limited role in esophageal cancer. The majority have systemic disease at presentation, minimal residual disease following resection or co-morbid conditions that preclude extensive surgery. This paper examines whether neoadjuvant therapy is effective in advanced-stage disease. A randomized trial, closing September 1995, was followed up to determine results at 5 years. All patients were followed up for more than 5 years. Median survival, based on intention-to-treat, was 17 months for multimodal therapy vs. 12 months for surgery alone (P=0.002). Survival based on treatment received was 27 months vs. 14 months (P=0.0006). Multimodal therapy enhances survival for patients with minimal residual disease. This is consistent with the literature. Under-powered trials cannot prove a real difference to be significant. Future trials should target patients with minimal residual disease.
Collections Ireland -> IT Blanchardstown -> PubMed

Full list of authors on original publication

A Kelly, S Mansoor, M Grennell, T N Walsh

Experts in our system

T N Walsh
IT Blanchardstown
Total Publications: 53